(Q33737387)

29 July 2017

1 reference

title

The initial treatment of Parkinson's disease should begin with levodopa (English)

1 reference

29 July 2017

1 reference

1 reference

Weiner WJ

1

1 reference

PubMed ID

10495031

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

14

1 reference

29 July 2017

5

1 reference

29 July 2017

716-724

1 reference

Multi-center study of Parkinson mortality with early versus later dopa treatment

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Levodopa: is toxicity a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l-DOPA and Carbidopa Chronically

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Is levodopa toxic to human substantia nigra?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Combined bromocriptine-levodopa therapy early in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Early combination therapy with bromocriptine and levodopa in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Does levodopa aggravate Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Subcutaneous apomorphine in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Early dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Pergolide in the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Dopamine agonists in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C716%3A%3AAID-MDS1002%3E3.0.CO%3B2-Q

10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10495031